{
    "root": "30b39516-075b-29f9-e063-6294a90ac30c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Estratest FS",
    "value": "20250310",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ESTROGENS, ESTERIFIED",
            "code": "3ASP8Q3768"
        },
        {
            "name": "METHYLTESTOSTERONE",
            "code": "V9EFU16ZIF"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        }
    ],
    "indications": "ESTRATEST H.S. AND ESTRATEST F.S. are indicated in the treatment of:  Moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.)\n                  \n                  ESTRATEST H.S. AND ESTRATEST F.S. HAVE NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING).",
    "contraindications": "1.\n  \n                        Given cyclically for short-term use only:\n                     \n                  \n                  For treatment of moderate to severe vasomotor symptoms associated with the menopause in patients not improved by estrogen alone.\n                  The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible.\n                  Administration should be cyclic (e.g., three weeks on and one week off). Attempts to discontinue or taper medication should be made at three- to six month intervals.\n                  \n                     \n                        2. Usual Dosage Range:\n                     \n                  \n                  1 tablet of ESTRATEST F.S. or 1 to 2 tablets of ESTRATEST H.S. daily as recommended by the physician.\n                  \n                     \nTreated patients with an intact uterus should be monitored closely for signs of endometrial cancer and appropriate diagnostic measures should be taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding.",
    "warningsAndPrecautions": "ESTRATEST F.S. in bottles of 100.\n  \nESTRATEST F.S. light green, oval-shaped, biconvex tablet debossed with \"640\" on one side and scripted \"E\" on other side.\n  \nContains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.\n  \nESTRATEST H.S. in bottles of 100.\n  \nESTRATEST H.S. dark green, oval-shaped, biconvex tablet debossed with \"639\" on one side and scripted \"E\" on other side.\n  \nContains: 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.\n  \nStore at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room\n  \nTemperature.]",
    "adverseReactions": "Estrogens should not be used in women with any of the following conditions:\n  \n1. Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic\n  \ndisease.\n  \n2. Known or suspected estrogen-dependent neoplasia.\n  \n3. Known or suspected pregnancy (See Boxed Warning).\n  \n4. Undiagnosed abnormal genital bleeding.\n  \n5. Active thrombophlebitis or thromboembolic disorders.\n  \n6. A past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use\n  \n(except when in treatment of breast malignancy).\n \n                  \n                     \nMethyltestosterone should not be used in:\n  \n1. The presence of severe liver damage.\n  \n2. Pregnancy and in breast-feeding mothers because of the possibility of masculinization of the female fetus or\n  \nbreast-fed infant."
}